Literature DB >> 22013812

[Sequential syndrome differentiation by eliminating pathogen and strengthening vital Qi on the basis of acute exacerbation of chronic obstructive pulmonary disease risk window].

Jian-sheng Li1, Hai-feng Wang.   

Abstract

Chronic obstructive pulmonary disease (COPD) remains a severe public health problem. Acute exacerbation of COPD (AECOPD) is a major factor that influences the process of COPD. Strengthening the treatment of AECOPD is very essential. AECOPD risk window (AECOPD-RW) refers to the period from AECOPD remission to the time before the stable phase. The condition is very unstable. Symptoms are relieved but continually exist. The lung function has not restored to the levels of the stable phase. The inflammatory reactions continually exist. In this period patients are most liable to suffer from AECOPD, resulting in higher hospital admission rate and higher mortality. Dispelling pathogens should be taken as the main principle for AECOPD treatment. However, when it transforms from AECOPD to AECOPD-RW, strengthening the body resistance should be taken as the main principle. The proposal of AECOPD-RW has provided new thoughts and strategies for COPD. In this period deficiency syndrome dominates, most being lingering pathogens due to deficient vital qi. Qi deficiency and qi-yin deficiency are the most common syndromes, involving Fei, Pi, and Shen. Deficiency of both Fei and Shen dominates, complicated with phlegm and stasis. Therefore, the treatment principle of AECOPD-RW should focus on tonifying the deficiency and strengthening the body resistance, assisted with dissipating phlegm and activating blood circulation.

Entities:  

Mesh:

Year:  2011        PMID: 22013812

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

1.  Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and "AECOPD Risk-Window": study protocol for a randomized placebo-controlled trial.

Authors:  Wang Haifeng; Li Jiansheng; Li Suyun; Yu Xueqing; Zhang Hailong; Wang Zhiwan; Wu Qiyi; Zhang Pankui; Wang Zhongchao; Li Fenglei; Yan Haihong
Journal:  Trials       Date:  2012-04-20       Impact factor: 2.279

2.  Effect of Liuweibuqi capsules on CD4+CD25+Foxp3+ regulatory T cells, helper T cells and lung function in patients with stable chronic obstructive pulmonary disease complicated with lung Qi deficiency.

Authors:  Cheng-Yang Wang; Huan-Zhang Ding; Xiao Tang; Ze-Geng Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Sequential Treatments with Tongsai and Bufei Yishen Granules Reduce Inflammation and Improve Pulmonary Function in Acute Exacerbation-Risk Window of Chronic Obstructive Pulmonary Disease in Rats.

Authors:  Xiaofan Lu; Ya Li; Jiansheng Li; Haifeng Wang; Zhaohuan Wu; Hangjie Li; Yang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-08-01       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.